全自动SARS-CoV-2 IgM和IgG免疫检测方法的开发及多中心性能评估
本研究开发了检测人血清中SARS-CoV-2 IgM和IgG抗体的全自动化学发光免疫分析方法,并在10家医院评估性能。采用972例住院患者和586例正常人群供者评估临床特异性,513例RT-PCR确诊病例评估临床敏感性。结果显示检测精密度CV<4.45%,标本灭活不影响测定,IgM和IgG均显示高临床特异性和敏感性,对核酸检测是有力补充。
要点
- 全自动化学发光法检测SARS-CoV-2 IgM/IgG抗体精密度CV<4.45%,标本灭活不影响检测。
- IgM临床特异性住院患者97.33%、正常人群99.49%;IgG分别为97.43%、99.15%。
- 症状出现7-14天IgM敏感性92.93%、IgG 97.98%;14天后IgG敏感性99.15%。
核心结论
- 开发的全自动SARS-CoV-2 IgM和IgG免疫检测方法具有高临床特异性和敏感性,对核酸检测是有力补充。
研究设计与样本
- 在10家医院评估全自动化学发光免疫分析方法检测人血清SARS-CoV-2 IgM和IgG抗体的性能。
- 临床特异性评估纳入972例住院患者和586例正常人群供者;临床敏感性评估纳入513例RT-PCR确诊病例。
主要发现
- 检测精密度系数变异小于4.45%,标本灭活不影响测定。
- SARS-CoV-2 IgM临床特异性住院患者97.33%、正常人群99.49%;IgG分别为97.43%、99.15%。
- 症状出现7天内、7-14天、14天后IgM临床敏感性分别为82.54%、92.93%、84.62%;IgG分别为80.95%、97.98%、99.15%。
临床怎么用
- 全自动SARS-CoV-2 IgM和IgG抗体检测可用于辅助核酸检测鉴别感染患者。
- 抗体检测敏感性随症状出现时间变化,应结合病程解读结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread globally. The laboratory diagnosis of SARS-CoV-2 infection has relied on nucleic acid testing; however, it has some limitations, such as low throughput and high rates of false negatives. Tests of higher sensitivity are needed to effectively identify infected patients. METHODS: This study has developed fully automated chemiluminescent immunoassays to determine IgM and IgG antibodies to SARS-CoV-2 in human serum. The assay performance has been evaluated at 10 hospitals. Clinical specificity was evaluated by measuring 972 hospitalized patients and 586 donors of a normal population. Clinical sensitivity was assessed on 513 confirmed cases of SARS-CoV-2 by RT-PCR. RESULTS: The assays demonstrated satisfied assay precision with coefficient of variation of less than 4.45%. Inactivation of specimen did not affect assay measurement. SARS-CoV-2 IgM showed clinical specificity of 97.33 and 99.49% for hospitalized patients and the normal population respectively, and SARS-CoV-2 IgG showed clinical specificity of 97.43 and 99.15% respectively. SARS-CoV-2 IgM showed clinical sensitivity of 82.54, 92.93, and 84.62% before 7 days, 7-14 days, and after 14 days respectively, since onset of symptoms, and SARS-CoV-2 IgG showed clinical sensitivity of 80.95, 97.98, and 99.15% respectively at the same time points above. CONCLUSIONS: We have developed fully automated immunoassays for detecting SARS-CoV-2 IgM and IgG antibodies in human serum. The assays demonstrated high clinical specificity and sensitivity, and add great value to nucleic acid testing in fighting against the global pandemic of the SARS-CoV-2 infection.
引用
- Qian C, Zhou M, Cheng F, et al. Development and multicenter performance evaluation of fully automated SARS-CoV-2 IgM and IgG immunoassays. Clin Chem Lab Med. 2020. PMID: 32609640. doi:10.1515/cclm-2020-0548
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。